Study Claims That MRI Scans Can Identify Breast Cancer Risk

Study Claims That MRI Scans Can Identify Breast Cancer Risk

According to a research, it may be possible to find multiple breast cancer biomarkers using magnetic resonance imaging (MRI) scans, which may aid in the early detection of the illness. Researchers from the Memorial Sloan Kettering Cancer Center in the US examined the healthy breast tissue of individuals with benign or non-cancerous breast tumors and malignant breast tumors, which may spread throughout the body.

They discovered that a variety of biomarker differences may be evaluated using positron-emission tomography (PET) or magnetic resonance imaging (MRI), which might aid in risk-reduction and screening methods.

In order to enhance prognosis and survival in cases of breast cancer, early diagnosis is still essential, according to a research published in The Journal of Nuclear Medicine.

Although screening mammography, which employs low-energy X-rays to inspect the human breast, has reduced breast cancer patients' death rates by 30%, it has a limited sensitivity and is less sensitive in women with thick breast tissue.

According to Doris Leithner, a research fellow at Memorial Sloan Kettering Cancer Center, "Such deficiencies demand additional advancements in breast cancer screening modalities, including the development of imaging biomarkers to guide follow-up therapy for breast cancer patients."

141 participants with imaging anomalies on mammography or sonography of a breast without tumors were included in the research.

The patients had combined PET/MRI of the breast using the radiotracer 18F-FDG as well as dynamic contrast-enhanced MRI and diffusion-weighted imaging (DWI).

The tumour-free breast of each patient had many imaging biomarkers, such as background parenchymal enhancement, breast parenchymal uptake, and fibroglandular tissue.

According to the researchers, two independent readers examined the variations between the biomarkers.

They reported that a total of 100 malignant and 41 benign lesions were evaluated.

Background parenchymal enhancement and breast parenchymal uptake in the contralateral breast tissue decreased and were substantially different in individuals with benign and malignant tumors.

Contralateral breast cancer (CBC) is a tumor in the breast on the other side that was found more than six months after the first malignancy was found.

On the basis of these findings, Leithner said, "tracer uptake of normal breast parenchyma in 18F-FDG PET could serve as another key, readily measurable imaging biomarker in breast cancer, analogous to breast density in mammography and background parenchymal enhancement in MRI."

He said that when hybrid PET/MRI scanners are utilized more often in clinical settings, they are able to concurrently evaluate and track a number of imaging biomarkers, including breast parenchymal uptake, which may help inform risk-adapted screening and risk-reduction tactics.